We report a strategy based on bioisosterism to improve the physicochemical properties of existing hydrophilic, urea-based GCPII inhibitors. Comprehensive structure-activity relationship studies of the P1 0 site of ZJ-43-and DCIBzL-based compounds identified several glutamate-free inhibitors with K i values below 20 nM. Among them, compound 32d (K i = 11 nM) exhibited selective uptake in GCPII-expressing tumors by SPECT-CT imaging in mice. A novel conformational change of amino acids in the S1 0 pharmacophore pocket was observed in the X-ray crystal structure of GCPII complexed with 32d.
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Glutamate carboxypeptidase II (GCPII) is a type II zinc-dependent metalloprotease that cleaves N-acetylaspartylglutamate (NAAG) to release N-acetylaspartate (NAA) and glutamate (Glu) in the brain. 1, 2 Excessive production and release of Glu in the synaptic cleft may over-stimulate glutamate receptors, leading to Gluassociated neurotoxicity and neuronal death. A glutamatergic imbalance has been proposed in the pathophysiology of a variety of neurological diseases including ischemia, traumatic brain injury, neuropathic pain, amyotrophic lateral sclerosis, diabetic polyneuropathy, and schizophrenia. [3] [4] [5] [6] [7] [8] Accordingly, maintaining Glu homeostasis at the synapse is a goal in the prevention and treatment of neuropsychiatric disease. Among the enzymes that modulate such Glu concentrations, GCPII is a potential target for effecting beneficial intrasynaptic Glu concentrations. GCPII has also been identified in non-neuronal tissues including kidney, small intestine, and prostate. Consequently GCPII has also been referred to as the prostate-specific membrane antigen (PSMA) in the prostate and as folate hydrolase (FOLH1) in the intestine. PSMA is over-expressed on the surface of androgen-independent prostate cancer cells and its active site is located in the extracellular region. Cell-surface expression and up-regulation in prostate tumors render PSMA an attractive target for the diagnosis and possibly therapy of prostate cancer. 9, 10 The FOLH1 activity of GCPII hydrolyzes c-linked glutamates from poly-c-glutamyl folate to produce folic acid, which can then be bound by folate receptors in the intestine. 11 GCPII has also been identified in neovasculature of most solid tumors. 12 That vascular expression enhances GCPII as a cancer imaging and therapeutic target. Previously, we have synthesized a number of urea-based GCPII inhibitors radiolabeled with 99m Tc, 125 I, 18 F and 11 C, which demonstrated strong GCPII inhibitory potency in vitro and selective uptake in PSMA-expressing tumors in vivo in single photon emission computed tomography (SPECT) and positron emission tomography (PET) small animal imaging studies. [13] [14] [15] [16] [17] Recent crystallographic studies of complexes between GCPII and low molecular weight ligands, including our urea-based inhibitors, elucidated their binding modes within the active site of GCPII, revealing that the S1 pocket of GCPII is more tolerant toward structural modification than the glutamate-binding, S1 0 (pharmacophore) pocket. [18] [19] [20] [21] [22] [23] [24] Consequently, we have taken advantage of the structural freedom provided by the S1 pocket for the development of imaging probes for prostate cancer.
In parallel with our effort to develop PSMA-based imaging agents for prostate cancer, we have attempted to develop imaging agents for Glu-associated neurological disease. Using in vitro autoradiography we previously determined GCPII levels in rodent brain by measuring specific binding of [ (Fig. 1) , a potent GCPII inhibitor. 24 By employing GCPII knockout mice, we showed that
]DCIT demonstrated binding to rodent brain in a GCPII genedose dependent fashion. Using a similar technique we reported that GCPII levels in prefrontal cortex and temporal lobe in postmortem samples of patients with schizophrenia were significantly lower than age-matched controls. 25 Another tricarboxylic acid with the urea core, ZJ-43 ( Fig. 1 ), exhibited strong in vitro GCPII inhibition (K i = 0.8 nM) with cloned human GCPII and demonstrated analgesic activity in inflammatory and neuropathic pain models. 26 However, high doses of ZJ-43 (50-100 mg/kg) needed to be administered in order to demonstrate an analgesic effect, due to low penetration of the blood-brain barrier (BBB). DCIBzL ( Fig. 1) , the most potent urea-based GCPII inhibitor (K i = 0.01 nM) that we have synthesized to date, showed high and prolonged tumor uptake as well as high target to nontarget tissue ratios in ex vivo biodistribution studies. 14 Based on these findings with existing urea-based GCPII inhibitors, we designed novel urea-based GCPII inhibitors with increased lipophilicity through two approaches: (1) bioisosterism of the P1 0 glutamate using two potent GCPII inhibitors ZJ-43 and DCIBzL as templates, and (2) prodrugs of DCIT, which is beyond the scope of this Letter. Here, we discuss the synthesis, structure-activity relationships (SAR), X-ray crystal structures and in vivo SPECT-CT imaging studies of new urea-based GCPII inhibitors designed for greater penetration of the BBB. The aim of this study was to identify novel scaffolds to replace Glu in the P1 0 site in order to improve BBB penetration by passive diffusion while retaining GCPII binding affinity needed for detection by imaging. The current work focused on replacing one of the three carboxylic acids in ZJ-43 and DCIBzL with more lipophilic functional groups.
Ever since urea-based dipeptides with high GCPII binding affinity were reported by Kozikowski and co-workers in 2000, a number of urea-based GCPII inhibitors as therapeutic or imaging agents have been synthesized and evaluated. [27] [28] [29] Two potent urea-based PSMA inhibitors, ZJ-43 and DCIBzL ( Fig. 1 ), were selected as templates for substituting Glu in the P1 0 site with bioisosteric functional groups. Compounds ZJ-43 and DCIBzL demonstrated potent in vitro GCPII inhibitory activities (K i = 0.8 nM and 0.01 nM) but have low C log D values (À6.1 and À5.16), too hydrophilic for the penetration of the BBB by passive diffusion. Recent site-directed mutagenesis experiments of amino acids in the vicinity of the GCPII active site revealed that mutation of the amino acids that contact the c-carboxylate of the P1 0 glutamate had less effect on enzymatic activity compared to mutation of those that contact the a-carboxylate in the P1 and P1 0 sites. 18 Therefore, we focused on modifications of the c-carboxylate group of the P1 0 site in ZJ-43 and DCIBzL in this study.
We replaced the side chain of the P1 0 glutamate moiety in ZJ-43 with a variety of more lipophilic bioisosteres including phenylgly- 30 and that external imaging can be observed with at least a 2:1 target:nontarget binding 31, 32 , we could establish a relationship between in vitro GCPII inhibitory activities and different substituents at the phenyl ring of the phenylglycine analog. Briefly, introduction of a hydroxyl group at the 4-position (3) led to an increase in GCPII inhibitory potency relative to substitution at the 3-position (1) or at 3,5-positions (4), indicating that 4-OH is preferred in this series. However, the replacement of 4-OH with 4-F resulted in a significant decrease in GCPII potency. Preference for a functional group at the 3-position along with 4-OH is as follows: OCH 3 (6) > I (8), Br (10) > F (12), suggesting that a bulky substituent at the 3-position slightly increased the binding affinity. Vanillin analog 7 (M.W. = 396.4, K i = 81 nM, C log D = À1.4), which has a hydroxyl group at the 4-position, a methoxy group at the 3-position and an isopropyl ester of leucine at the P1 site, was the most potent among the evaluated analogs. All compounds in the tyrosine (14) (15) (16) (17) (18) , methionine (19) (20) , glutamine (21), and tryptophan (22) series were less active than 7. However, because none of the ZJ-43 analogs showed an inhibitory activity lower than our initial 620 nM cut-off, we did not undertake in vivo studies.
To increase GCPII inhibitory potency of our bioisoteres, we synthesized analogs of DCIBzL (K i = 0.01 nM), one of the most potent GCPII urea-based inhibitors synthesized to date. 14 The crystal structure of GCPII complexed with DCIBzL (PDB ID: 3D7H) showed a peculiar binding pattern in the vicinity of the S1-pocket. 18 The iodophenyl group of DCIBzL projects into the arginine-patch region and resides in the accessory pocket delineated by side chains of arginines 463, 534 and 536 (Fig. 3) . The utilization of that subpocket increases DCIBzL potency by more than 80-fold compared to ZJ-43. We hypothesized that the iodophenyl-substituted lysine moiety in place of the leucine of ZJ-43 would increase the binding affinity for GCPII.
To confirm the importance of the c-and a-carboxylic acid groups at the P1 0 site, we replaced the P1 0 glutamic acid with glycine (32a) and c-aminobutyric acid (32b), respectively. Both substitutions resulted in a dramatic decrease of GCPII inhibitory activity, indicating that both the a-and c-carboxylates are important for GCPII binding although the glycine analog (32a, 1.32 lM) is slightly more potent than the GABA analog (32b, 3.43 lM). However, cyclopropanylglycine analog (32c, 318 nM) showed fourfold stronger binding affinity for GCPII than 32a, implying that a substituent at the a-carbon of the glycine may increase the binding potency. Encouraged by that result, we focused on the modification on the P1 0 side chain of DCIBzL (bearing the c-carboxylic functionality) using substituted glycines.
The synthesis of DCIBzL analogs is shown in Scheme 3. Briefly, N e -Boc-L-lysine-t-butyl ester was reacted with triphosgene and triethylamine in dichloromethane, followed by the addition of unnatural amino acid, to afford compounds in 30-70% yield. Protecting groups (t-butyl and Boc) were removed by the treatment with TFA. The terminal amine of Lys was coupled with N-succinimidyl-4-iodobenzoate to give compounds 32a-32t (Scheme 3) in 50-75% yield. Table 1 summarizes the K i values and C log D values of DCIBzL analogs. Introduction of hydrocarbon groups, which are more flexible and bulky than cyclopropane, resulted in a substantial increase in GCPII inhibitory activity. In particular, unsaturated hydrocarbon groups such as allylic (32d, 11 nM) and propargylic (32e, 5.3 nM) increased potency of GCPII inhibitory activity more significantly than the corresponding saturated analog (32f, 52.3 nM). However, analogs with heteroatom-containing functional groups including epoxide (32g), nitrile (32h) and amide (32i) were less active, with K i values over 100 nM. Nevertheless, K i values of sulfur-containing analogs (32j and 32k) were 23 nM and 24 nM, respectively. Phen- ylglycine analogs 32l (85 nM) and 32m (285 nM) were not as potent as 32j and 32k.
To investigate the effects of stereochemistry on GCPII binding, compounds 32n-q were synthesized. Maintenance of natural stereochemistry at the a-carbon is critical for GCPII inhibitory activity.
Compounds 32n (5.3 nM) and 32o (16.2 nM), which have (L)-configuration at the a-carbon, are much more potent than the corresponding (D)-analogs 32p (794 nM) and 32q (795 nM). Thiazolesubstituted 32r (16.1 nM) displayed strong potency, similar to the thiophene-containing 32o. However, compounds 32s (105 nM) and 32t (97 nM), substituted with a pyridine function, exhibited weaker inhibitory potency than the five-membered heteroaromatic analogs (32n, 32o and 32r). Compound 32d was further studied in vivo because it demonstrated a K i value of 11 nM, which is below the theoretical cut-off value (K i 620 nM) for visualization by external imaging. 31, 32 Compound [ To elucidate the binding mode of 32d in the active site of GCPII, we determined the X-ray crystal structure of GCPII in complex with 32d (PDB ID: 3IWW). As shown in Figure 3 , 32d (represented in green) is positioned in the GCPII binding cavity in a manner similar to DCIBzL. 18 The 4-iodobenzoyl moiety resides inside the pocket accessory to the S1 site and participates in p-cationic interactions with the guanidinium groups of Arg534 and Arg463. The urea carbonyl group interacts with the hydroxyl group of the Tyr552 and both P1 and P1 0 a-carboxylates are engaged primarily by the guanidinium groups of Arg534 and Arg536 (P1) and Arg210 (P1 0 ), respectively. The allylic moiety spatially overlaps with the side chain of the P1 0 glutamate in DCIBzL, but the absence of interactions between the P1 0 side chain of 32d and the Lys699 and Asn257 (as observed in the case of P1 0 glutamate) reduces somewhat its GCPII inhibitory potency. Nevertheless, the allyl side chain contributes to the potency of 32d, primarily via non-polar interactions with the side chains of Phe209, Leu261, and Leu428. This contribution is clearly documented by 120-fold tighter binding compared to compound 32a, which is missing the P1 0 side chain altogether. Interestingly, an association with 32d is accompanied by structural rearrangements at the bottom of the GCPII-S1
0 pocket, including displacement of the Lys699 side chain and a repositioning of the Leu259-Gly263 segment (Fig. 3) . Such variability has not been observed in any published GCPII structure and indicates additional spatial freedom of the S1 0 pocket that could be used for inhibitor design.
In summary, the SAR studies of ZJ-43 and DCIBzL analogs described herein have identified new scaffolds to replace the glutamic acid in the P1 0 region. These include the allyl, alkynl, furanyl, and thiophenyl moieties. Among them, compound 32d, containing the allylic moiety, exhibited selective uptake in PSMA-positive tumors in SPECT-CT imaging studies. The GCPII crystal structure with 32d showed a binding pattern similar to DCIBzL in the active site, along with a unique conformational change in the S1 0 pocket. However, compound 32d is still too hydrophilic for brain imaging, suggesting that further structural modification is warranted.
